替吉奥治疗老年晚期鼻咽癌临床疗效与安全性  

Efficacy and Safety of S-1 in Elderly Patients with Advanced Nasopharyngeal Carcinoma

作　　者：朱美琴[1] 夏俊贤[1] 徐敏[1] 陈敬华[1] 申维玺[1] 

机构地区：[1]暨南大学第二临床医学院深圳市人民医院肿瘤内科,深圳市518020

出　　处：《中国医药导刊》2014年第1期107-108,110,共3页Chinese Journal of Medicinal Guide

摘　　要：目的：观察替吉奥单药治疗老年晚期鼻咽癌临床疗效与安全性。方法：选取2011年5月至2012年5月在我院治疗的60例老年晚期鼻咽癌患者为研究对象。随机将其分为替吉奥组（S组）与5-氟尿嘧啶组（F组）。替吉奥组30例（S组）：替吉奥（40-60）mg（＜1.25 m2,40mg；1.25-1.5 m2,50mg；＞1.5 m2,60mg）,于早、晚饭后口服,连服14天,21天重复。5-氟尿嘧啶组（F组）采用注射液进行给药治疗,21天重复,至少两周期后评价疗效。综合有效率指标及副作用产生情况判断替吉奥与5-氟尿嘧啶治疗老年晚期鼻咽癌临床疗效。结果：两组患者治疗后,癌症状况均有良好改善,但替吉奥组临床效果优于5-氟尿嘧啶组,替吉奥组有效率为86.67%,5-氟尿嘧啶组有效率为63.33%,P〈0.05,差异具有统计学意义。中位疾病进展时间（TTP）为8.1个月和7.6个月,P〉0.05,差异没有统计学意义。中位生存时间（OS）为18.3个月和16.5个月,P〉0.05,差异没有统计学意义。副作用方面,两组患者治疗后的不良反应均可耐受,差异不明显。结论：采用替吉奥治疗老年晚期鼻咽癌疗效肯定,耐受性好,值得临床进一步推广。Objective：To compare the clinical effect of S-1 and 5-fluorouracil in the treatment of elderly patients with advanced nasopharyngeal carcinoma.Methods：60 elderly patients with nasopharyngeal carcinoma were admitted from May 2011 to May 2012. The study group（S group,n=30）：S-1：（40-60）mg（〈1.25m2,40mg;（1.25-1.5m2,50）mg;〉1.5 m2,60mg） ,twice/day,oral administration,d1-14,three weeks was a cycle. The control group（F group,n=30）：5-Fu 500mg/m2/d,intravenous infusion,d1-5, three weeks was a cycle. The efficacy and toxicity were evaluated by WHO stardards after 2 cycles.Results：All the two groups were improved after treatments.But the S group was better than the F group.The RR of S group and F group was 86.67%and 63.33%.There was significant difference （P〈0.05）. The median TTP was 8.1 and 7.6 months.There was no significant difference （P〉0.05）. The median OS was 18.3 and 16.5 months.There was no significant difference （P〉0.05）.The most common toxicities of the two groups could be well tolerated. There was no significant difference （P〉0.05）.Conclusion：The efficacy of S-1 for elderly patients with nasopharyngeal carcinoma is significant with well-tolerated toxicity ,and worth to further study and popularize.

关 键 词：替吉奥 5-氟尿嘧啶 老年 鼻咽癌 临床疗效 

分 类 号：R739.63[医药卫生—肿瘤]